Skip to main content

Drug Safety

      RT @swethaann23: Baseline/ Clinical /Imaging predictors of flare when tapering TNFI in axSpA in remission:

      ⭐️🔼Ba

      swethaann23 swethaann23

      3 years 11 months ago
      Baseline/ Clinical /Imaging predictors of flare when tapering TNFI in axSpA in remission: ⭐️🔼Baseline physician global VAS 🔼flare in 16 weeks after tapering to 2/3 of standard dose. ⭐️🔼Age 🔼flare within 16 weeks after tapering to 1/2 dose Abst #0929 #ACR21 @RheumNow https://t.co/EFiwKA8z99
      RT @ericdeinmd: #ACR21 Abst#0588. TNF vs non-TNFi in obese RA pts
      ⭐️TNFi use ⬆️ disease activity vs ABA in obese

      Eric Dein ericdeinmd

      3 years 11 months ago
      #ACR21 Abst#0588. TNF vs non-TNFi in obese RA pts ⭐️TNFi use ⬆️ disease activity vs ABA in obese pts ⭐️TNFi use ⬆️ activity vs TCZ in non-obese pts ⭐️No diff w RTX, Tofa ▶️Further research needed: Wt-based dosing? SC vs IV? https://t.co/K8WycPTgxW @Rheumnow #ACRBest
      RT @drdavidliew: Let's look at MI first.
      Well, the numbers don't look great for tofa here.

      fatal MI very small numbers

      David Liew drdavidliew

      3 years 11 months ago
      Let's look at MI first. Well, the numbers don't look great for tofa here. fatal MI very small numbers non-fatal MI - well that doesn't look good (do we have combined both tofa doses vs TNFi?) HR > 2 seems less than ideal - this would represent a substantial RF #ACR21 @RheumNow https://t.co/5HSXFrMJCu
      RT @KDAO2011: Do you order EKGs in everyone starting HCQ? Do you avoid HCQ in patients with heart failure? Will these ab

      TheDaoIndex KDAO2011

      3 years 11 months ago
      Do you order EKGs in everyone starting HCQ? Do you avoid HCQ in patients with heart failure? Will these abstracts impact your practice? Click on link to read more....#ACR21 @rheumnow #HCQ https://t.co/fvUZAvNWa8
      RT @RichardPAConway: Dr Naovarat reports on 18 year outcomes of HIV and rheumatic disease. 16 patients treated with TNFi

      Richard Conway RichardPAConway

      3 years 11 months ago
      Dr Naovarat reports on 18 year outcomes of HIV and rheumatic disease. 16 patients treated with TNFi, including 2 who switched to tocilizumab and ustekinumab. No major infections. Rising viral load in 1 led to discontinue. Abstr#0965 #ACR21 @RheumNow https://t.co/jcGPaURKmb
      RT @doctorRBC: Physician global score only predictor of axSpA flares when tapering TNFi
      ⭐️Changes in imaging did no

      Robert B Chao, MD doctorRBC

      3 years 11 months ago
      Physician global score only predictor of axSpA flares when tapering TNFi ⭐️Changes in imaging did not predict flare Abs#929 #ACR21 @RheumNow https://t.co/vVn6ARKJu0 https://t.co/FlVtlLmTfl
      RT @drdavidliew: For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunog

      David Liew drdavidliew

      3 years 11 months ago
      For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunogenicity not an issue, is that actually true? Canadian registry data: maybe no after 36m, low no. ?valid, markups mine Need to see more of this! #ACR21 ABST0827 ⁦@RheumNow⁩ https://t.co/VVwd4SZgVx
      Best of PsA Saturday: Dr Rachel Tate
      RT @ericdeinmd: #ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX:
      ▶️No significant correlation b

      Eric Dein ericdeinmd

      3 years 11 months ago
      #ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX: ▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX. ⭐️Age, sex, waist circumference, BMI are risks @Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7
      Perspectives on TNFi: Dr. Jon Giles
      RT @AurelieRheumo: TNFi + JIA = watch the skin! A nearly 3fold increase of paradoxal psoriasis in JIA patients exposed t

      Aurelie Najm AurelieRheumo

      3 years 11 months ago
      TNFi + JIA = watch the skin! A nearly 3fold increase of paradoxal psoriasis in JIA patients exposed to TNFi reported in the CARRA registry w/ incidence rate the highest on children receiving adalimumab. #Abst0241 @RheumNow #ACR2021 https://t.co/uXOwV2RlGu https://t.co/8f8mvVUkV2
      Opening Day Report
      The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford). The Year in Review featured a clinical vs basic science Brigham and Women’s Hospital faceoff between its two faculty, Dr. Karen Costenbader and Dr. Michael Brenner.
      Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.
      ×